Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review
The use of poly (ADP-ribose) polymerase (PARP) inhibitors has recently increased as a result of demonstrating their superior efficacy compared to traditional chemotherapy in various cancer subtypes in many preclinical studies and clinical trials. A better understanding of the molecular mechanisms o...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2022-12-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/41206 |
| _version_ | 1797977644601442304 |
|---|---|
| author | Emilia Nowicka Michał Obel Kinga Panuciak Angelika Mastalerczyk Kamila Czyżak Jan Lejman Karolina Makowska Wiktor Wiśniewski |
| author_facet | Emilia Nowicka Michał Obel Kinga Panuciak Angelika Mastalerczyk Kamila Czyżak Jan Lejman Karolina Makowska Wiktor Wiśniewski |
| author_sort | Emilia Nowicka |
| collection | DOAJ |
| description |
The use of poly (ADP-ribose) polymerase (PARP) inhibitors has recently increased as a result of demonstrating their superior efficacy compared to traditional chemotherapy in various cancer subtypes in many preclinical studies and clinical trials. A better understanding of the molecular mechanisms of PARP and their underlying foci that can be used as screening markers for potential new therapeutic options would aid rational treatment strategies and improve long-term patient outcomes. The available data on acute leukemia suggest potential windows for effective treatment of PARPi in disease subgroups. In this review, we summarize the current advances in the most common PARP-based adjuvant therapies and combination strategies for the treatment of acute leukemia and discuss the future prospects and challenges of therapy with PARP inhibitors. We also discuss reports describing an increased risk of cancer treatment in patients receiving PARP inhibitors for solid tumors.
The research material were publications, the search was carried out using a combination of keywords such as: "PARP inhibitor", "acute leukemia", "therapy", "PARP clinical trials". The first step was to find relevant publications from the last 15 years. The second step was to review the publications found.
Studies have shown that PARP inhibitors play an increasing role in the treatment of leukemia. In addition, focusing research efforts on identifying the most effective drug combinations and sequences could help to further shape the role of PARPi in the treatment of acute myeloid leukemia (AML).
|
| first_indexed | 2024-04-11T05:11:19Z |
| format | Article |
| id | doaj.art-e58ebbaf459c458cb24edf9e6a436f74 |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-04-11T05:11:19Z |
| publishDate | 2022-12-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-e58ebbaf459c458cb24edf9e6a436f742022-12-25T11:41:31ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062022-12-0113210.12775/JEHS.2023.13.02.014Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature reviewEmilia Nowicka0Michał Obel1Kinga Panuciak2Angelika Mastalerczyk3Kamila Czyżak4Jan Lejman5Karolina Makowska6Wiktor Wiśniewski7Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 LublinUniwersytet Medyczny w LublinieStudent Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 LublinStudent Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 LublinStudent Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 LublinStudent Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 LublinStudent Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 LublinEMC Clinic, Łowiecka Street 24, 50-220 Wrocław The use of poly (ADP-ribose) polymerase (PARP) inhibitors has recently increased as a result of demonstrating their superior efficacy compared to traditional chemotherapy in various cancer subtypes in many preclinical studies and clinical trials. A better understanding of the molecular mechanisms of PARP and their underlying foci that can be used as screening markers for potential new therapeutic options would aid rational treatment strategies and improve long-term patient outcomes. The available data on acute leukemia suggest potential windows for effective treatment of PARPi in disease subgroups. In this review, we summarize the current advances in the most common PARP-based adjuvant therapies and combination strategies for the treatment of acute leukemia and discuss the future prospects and challenges of therapy with PARP inhibitors. We also discuss reports describing an increased risk of cancer treatment in patients receiving PARP inhibitors for solid tumors. The research material were publications, the search was carried out using a combination of keywords such as: "PARP inhibitor", "acute leukemia", "therapy", "PARP clinical trials". The first step was to find relevant publications from the last 15 years. The second step was to review the publications found. Studies have shown that PARP inhibitors play an increasing role in the treatment of leukemia. In addition, focusing research efforts on identifying the most effective drug combinations and sequences could help to further shape the role of PARPi in the treatment of acute myeloid leukemia (AML). https://apcz.umk.pl/JEHS/article/view/41206PARP inhibitorDrug targetsCombination therapiesAcute leukemiaAcute Myeloid Leukemia |
| spellingShingle | Emilia Nowicka Michał Obel Kinga Panuciak Angelika Mastalerczyk Kamila Czyżak Jan Lejman Karolina Makowska Wiktor Wiśniewski Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review Journal of Education, Health and Sport PARP inhibitor Drug targets Combination therapies Acute leukemia Acute Myeloid Leukemia |
| title | Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review |
| title_full | Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review |
| title_fullStr | Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review |
| title_full_unstemmed | Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review |
| title_short | Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review |
| title_sort | poly adp ribose polymerase parp inhibitors new therapeutic strategies in acute myeloid leukemia a literature review |
| topic | PARP inhibitor Drug targets Combination therapies Acute leukemia Acute Myeloid Leukemia |
| url | https://apcz.umk.pl/JEHS/article/view/41206 |
| work_keys_str_mv | AT emilianowicka polyadpribosepolymeraseparpinhibitorsnewtherapeuticstrategiesinacutemyeloidleukemiaaliteraturereview AT michałobel polyadpribosepolymeraseparpinhibitorsnewtherapeuticstrategiesinacutemyeloidleukemiaaliteraturereview AT kingapanuciak polyadpribosepolymeraseparpinhibitorsnewtherapeuticstrategiesinacutemyeloidleukemiaaliteraturereview AT angelikamastalerczyk polyadpribosepolymeraseparpinhibitorsnewtherapeuticstrategiesinacutemyeloidleukemiaaliteraturereview AT kamilaczyzak polyadpribosepolymeraseparpinhibitorsnewtherapeuticstrategiesinacutemyeloidleukemiaaliteraturereview AT janlejman polyadpribosepolymeraseparpinhibitorsnewtherapeuticstrategiesinacutemyeloidleukemiaaliteraturereview AT karolinamakowska polyadpribosepolymeraseparpinhibitorsnewtherapeuticstrategiesinacutemyeloidleukemiaaliteraturereview AT wiktorwisniewski polyadpribosepolymeraseparpinhibitorsnewtherapeuticstrategiesinacutemyeloidleukemiaaliteraturereview |